Related Experiment Video
Updated: Jul 29, 2025
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.4K
The Heart Failure Knights
Chiara Mozzini1, Mauro Pagani1
1Department of Medicine, ASST Mantova, C. Poma Hospital, Mantova, Italy.
Current Problems in Cardiology
|May 27, 2023
Summary
New heart failure (HF) treatments focus on four drug classes and novel agents. Vericiguat shows promise, while myosin activators and inhibitors are under investigation for improved HF outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Translational Medicine
Background:
- The 2021 European Society of Cardiology guidelines shifted from sequential to a four-pillar approach for heart failure (HF) management in reduced ejection fraction HF (HFrEF).
- Recent clinical trials have introduced novel therapeutic agents beyond the established four pillars.
Purpose of the Study:
- To review emerging molecular therapies for HFrEF, examining their efficacy and potential as future treatments.
- To highlight new agents like vericiguat, omecamtiv mecarbil, aficamten, and mavacamten.
Main Methods:
- Review of recent clinical trial data and guideline updates for HFrEF.
- Analysis of novel drug classes targeting different mechanisms in heart failure.
Main Results:
- Vericiguat, a soluble guanylate cyclase stimulator, demonstrated efficacy in hospitalized HFrEF patients.
- Omecamtiv mecarbil (cardiac myosin activator) reduced HF events and cardiovascular death.
- Aficamten and mavacamten (cardiac myosin inhibitors) improved functional capacity in hypertrophic cardiomyopathy by reducing hypercontractility.
Conclusions:
- Novel agents like vericiguat, omecamtiv mecarbil, aficamten, and mavacamten represent promising advancements in HFrEF treatment.
- These emerging therapies offer new strategies to improve outcomes for patients with heart failure.
Related Concept Videos
01:30Heart Failure VII: Nursing Interventions
121
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
121
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:21Rheumatic Heart Disease III: Medical Management
22
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22
01:28Mitral Regurgitation IV: Nursing Management
51
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
51
01:30Heart Failure IV: Classification and Diagnostic Evaluation
21
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
21
01:22Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17